Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended

2024-517817-34-00 Gastric Cancer 2025-06-18
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended

2024-517818-15-00 Non-Small Cell Lung Cancer 2025-06-06
A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef… Ended

2024-515907-20-00 Primary biliary cholangitis (PBC) 2025-05-23
Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors Ended

2024-517952-37-00 Locally advanced or metastatic cancer (Solid tumors) 2025-05-22
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended

2024-517741-14-00 advanced non-squamous non-small cell lung cancer (NSCLC 2025-04-22
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended

2024-513738-39-00 IDH1-mutant Glioma 2025-03-18
Safety and exploratory efficacy of AMT-162 for adults with SOD1 ALS Ended

2024-517244-57-00 Amyotrophic Lateral Sclerosis (ALS) 2025-03-03
HOVON 172 MF: Study on tasquinimod treatment in patients with myelofibrosis Ended

2024-511565-11-00 Myelofibrosis 2025-02-12
A Phase 1b/2a, open-label single ascending doses and multiple ascending doses study in participants with Pi*ZZ AATD Ended

2024-511981-36-00 Alpha-1 antitrypsin deficiency (AATD) 2025-01-06
A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde… Ended

2023-509460-19-00 Muscle Invasive bladder cancer 2024-10-11
A phase 1/2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment… Ended

2024-515936-62-00 Patients with advanced or metastatic gastrointestinal ( 2024-10-10
An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Pa… Ended

2024-511212-24-00 Advanced solid tumors 2024-10-07
Study of the impact of DPD activity on the efficacy of capecitabine Ended

2024-517481-41-00 breast cancer 2024-10-02
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Breast Cancer 2024-10-02
SAFETY AND FEASIBILITY OF IRRADIATION AND NIVOLUMAB IN ESOPHAGEAL CANCER (INEC-STUDY) – A PHASE I/II TRIAL Ended

2023-510124-77-01 Eosophageal cancer 2024-09-28
DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves… Ended

2022-502640-12-01 Non-small cell lung cancer (NSCLC) 2024-09-27
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended

2023-509716-29-00 Solid Tumors, Colorectal Cancer and Breast Cancer 2024-09-23
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended

2022-501452-29-00 Metastatic Non-small Cell Lung Cancer 2024-08-28
STUDY AGORA-1 / ALFA 2100: Phase 2 on the combinaison of Gemtuzumab Ozogamicin witk gilteritinib in adult patients with acute myeloid leukem… Ended

2023-504176-25-00 Acute Myeloid Leukemia 2024-08-08
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended

2023-508256-19-00 Unresectable Metastatic Non-small Cell Lung Cancer 2024-07-15
AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended

2023-508130-33-00 ADVANCED OR METASTATIC BREAST CANCER 2024-07-03
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… Ended

2023-509678-52-00 Alzheimer's disease 2024-06-27
A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended

2023-507995-33-00 MSI-H/dMMR Gastric cancer 2024-05-23
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral… Ended

2024-511172-33-00 Gaucher Disease Type 1 2024-05-10